Splenectomy Effects on Chemotherapy in Hodgkin's Disease

Frank Panettiere, Charles A. Coltman

Research output: Contribution to journalArticlepeer-review

21 Scopus citations


We examined splenectomy effect on subsequent administration of intensive, intermittent combination chemotherapy in patients with disseminated Hodgkin's disease. Otherwise comparable patients with Hodgkin's disease received more chemotherapeutic agents in a shorter period of time when they had undergone prior splenectomy. Asplenic patients had higher circulating platelet and lymphocyte counts prior to chemotherapy onset, most likely due to removing a splenic pool of these cells. After four courses of chemotherapy there was a proportionately greater fall in the white blood cell and platelet counts in the asplenic group. This indicates that asplenic patients tolerated delivery of greater amounts of drug in shorter periods of time, and this is reflected in their greater degree of myelosuppression. Preliminary data suggest that there may be enhanced response rate in the asplenic group.

Original languageEnglish (US)
Pages (from-to)362-366
Number of pages5
JournalArchives of Internal Medicine
Issue number3
StatePublished - Mar 1973
Externally publishedYes

ASJC Scopus subject areas

  • Internal Medicine


Dive into the research topics of 'Splenectomy Effects on Chemotherapy in Hodgkin's Disease'. Together they form a unique fingerprint.

Cite this